Cargando…

The prevalence of cardiovascular disease and antidiabetes treatment characteristics among a large type 2 diabetes population in the United States

OBJECTIVES: The purpose of this study was to assess atherosclerotic cardiovascular disease (ASCVD) prevalence, antidiabetes medication usage and physician specialty encounters among individuals with type 2 diabetes mellitus (T2DM) in the United States during 2015. DESIGN: Retrospective, cross‐sectio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weng, Wayne, Tian, Ye, Kong, Sheldon X., Ganguly, Rahul, Hersloev, Malene, Brett, Jason, Hobbs, Todd
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613222/ https://www.ncbi.nlm.nih.gov/pubmed/31294089 http://dx.doi.org/10.1002/edm2.76

Ejemplares similares

The prevalence of cardiovascular disease by vascular bed and impact on healthcare costs in a large, real‐world population with type 2 diabetes
por: Weng, Wayne, et al.
Publicado: (2020)

Impact of atherosclerotic cardiovascular disease on healthcare resource utilization and costs in patients with type 2 diabetes mellitus in a real-world setting
por: Weng, Wayne, et al.
Publicado: (2020)

Antidiabetic treatment patterns and specialty care utilization among patients with type 2 diabetes and cardiovascular disease
por: Pantalone, Kevin M., et al.
Publicado: (2018)

Changes in Characteristics and Treatment Patterns of Patients with Newly Diagnosed Type 2 Diabetes in a Large United States Integrated Health System between 2008 and 2013
por: Pantalone, Kevin M., et al.
Publicado: (2016)

Treatment patterns and clinical characteristics of patients with type 2 diabetes mellitus according to body mass index: findings from an electronic medical records database
por: Weng, Wayne, et al.
Publicado: (2017)

The Probability of A1C Goal Attainment in Patients With Uncontrolled Type 2 Diabetes in a Large Integrated Delivery System: A Prediction Model
por: Pantalone, Kevin M., et al.
Publicado: (2020)

Clinical characteristics, complications, comorbidities and treatment patterns among patients with type 2 diabetes mellitus in a large integrated health system
por: Pantalone, Kevin M, et al.
Publicado: (2015)

Natural Language Processing Improves Detection of Nonsevere Hypoglycemia in Medical Records Versus Coding Alone in Patients With Type 2 Diabetes but Does Not Improve Prediction of Severe Hypoglycemia Events: An Analysis Using the Electronic Medical Record in a Large Health System
por: Misra-Hebert, Anita D., et al.
Publicado: (2020)

Prevalence and recognition of obesity and its associated comorbidities: cross-sectional analysis of electronic health record data from a large US integrated health system
por: Pantalone, Kevin M, et al.
Publicado: (2017)

Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom
por: Brunetti, Vanessa C., et al.
Publicado: (2022)

Cardiovascular outcomes and safety with antidiabetic drugs
por: Aldossari, Khaled K.
Publicado: (2018)

Repurposing Antidiabetic Drugs for Cardiovascular Disease
por: Schubert, Mario, et al.
Publicado: (2020)

Efficacy and Cardiovascular Safety of Antidiabetic Medications
por: Pappachan, Joseph M.
Publicado: (2021)

Quantifying the economic burden of unintended pregnancies due to drug–drug interactions with hormonal contraceptives from the United States payer perspective
por: Srinivasan, Meenakshi, et al.
Publicado: (2021)

Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes
por: Fisman, Enrique Z., et al.
Publicado: (2015)

Cardiovascular Safety of Oral Antidiabetic Medications: Need of the Hour
por: Kaduskar, Prashant Ulhas
Publicado: (2017)

Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes
por: Lo, Chris Wai Hang, et al.
Publicado: (2021)

Antidiabetic Action of Bezafibrate in a Large Observational Database
por: Flory, James H., et al.
Publicado: (2009)

AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases
por: Lu, Qingguo, et al.
Publicado: (2019)

Beyond Blood Sugar: Investigating the Cardiovascular Effects of Antidiabetic Drugs
por: Ahmad, Binish A, et al.
Publicado: (2023)

Cardiovascular Outcome Studies With Novel Antidiabetes Agents: Scientific and Operational Considerations
por: Hirshberg, Boaz, et al.
Publicado: (2013)

Recent cardiovascular outcome trials of antidiabetic drugs: A comparative analysis
por: Singh, Awadhesh Kumar, et al.
Publicado: (2017)

Antidiabetic and cardiovascular beneficial effects of a liver-localized mitochondrial uncoupler
por: Kanemoto, Naohide, et al.
Publicado: (2019)

Physicochemical Characteristics and Antidiabetic Properties of the Polysaccharides from Pseudostellaria heterophylla
por: Liu, Yingying, et al.
Publicado: (2022)

Impact of diabetes mellitus on risk of cardiovascular disease and all-cause mortality: Evidence on health outcomes and antidiabetic treatment in United States adults
por: Liu, Longjian, et al.
Publicado: (2016)

Cardiovascular Benefits of New Antidiabetic Drug Classes: A Network Meta-analysis
por: Cheung, BMY, et al.
Publicado: (2020)

Meta‐analysed numbers needed to treat of novel antidiabetic drugs for cardiovascular outcomes
por: Wolff, Georg, et al.
Publicado: (2022)

Association of clinical characteristics, antidiabetic and cardiovascular agents with diabetes mellitus and COVID-19: a 7-month follow-up cohort study
por: Pazoki, Marzieh, et al.
Publicado: (2021)

CKD Prevalence Among Patients With and Without Type 2 Diabetes: Regional Differences in the United States
por: Feng, Xue (Snow), et al.
Publicado: (2021)

The Antidiabetic Functions of the Pancreas and Successful Isolation of the Antidiabetic Hormone Insulin
Publicado: (1924)

Aspirin for cardiovascular disease prevention among adults in the United States: Trends, prevalence, and participant characteristics associated with use
por: Boakye, Ellen, et al.
Publicado: (2021)

Design and in vitro characterization of novel pulsatile delivery system of biguanide antidiabetic drug
por: Pandey, Rahul, et al.
Publicado: (2020)

Using real world data to assess cardiovascular outcomes of two antidiabetic treatment classes
por: Stapff, Manfred Paul
Publicado: (2018)

Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis
por: Fei, Yue, et al.
Publicado: (2019)

Prevalence and Characteristics of Telehealth Utilization in the United States
por: Fischer, Shira H., et al.
Publicado: (2020)

Characteristics of Food Protein-Derived Antidiabetic Bioactive Peptides: A Literature Update
por: Nong, Nhung Thi Phuong, et al.
Publicado: (2021)

Antidiabetic Effects of Tea
por: Fu, Qiu-Yue, et al.
Publicado: (2017)

SGLT inhibitors as antidiabetic agents: a comprehensive review
por: Kshirsagar, Rahul P., et al.
Publicado: (2020)

Combining insulins with oral antidiabetic agents: effect on hyperglycemic control, markers of cardiovascular risk and disease
por: Hermansen, Kjeld, et al.
Publicado: (2008)

Impact of the U.S. Food and Drug Administration Cardiovascular Assessment Requirements on the Development of Novel Antidiabetes Drugs
por: Hirshberg, Boaz, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_84hrdf5cect26jiktnkp1jrsc8